Heart Failure

Five things for pharma marketers to know: Tuesday, October 25, 2016

Five things for pharma marketers to know: Tuesday, October 25, 2016

By

Novartis' Entresto and Cosentyx miss sales forecasts; faith-based investor group urges pricing transparency; Amgen invests in digital health

Novartis ups marketing investment in Entresto, by $200 million

Novartis ups marketing investment in Entresto, by $200 million

By

One oft-cited challenge to Entresto's adoption has been prior authorization requirements.

Practice Fusion founder launches heart-monitoring wearable

Practice Fusion founder launches heart-monitoring wearable

By

The new company, iBeat, plans to market a wearable device that can detect the symptoms of cardiac arrest and heart attacks.

Five things for pharma marketers to know: Thursday, May 19, 2016

Five things for pharma marketers to know: Thursday, May 19, 2016

By

Novartis plans new trials for Entresto; U.S. spending on mental health topped $201 billion in 2013; the FDA approves Roche's immunotherapy drug

Novartis: Cardiologists slow to advocate on behalf of new drugs

Novartis: Cardiologists slow to advocate on behalf of new drugs

By

The drugmaker said Entresto, its new heart-failure drug, brought in "modest sales" in the third quarter of 2015.

Five things for pharma marketers to know: Monday, September 14, 2015

Five things for pharma marketers to know: Monday, September 14, 2015

By

Entresto's price is too high; Shire may increase its bid for Baxalta; Sanofi's experimental diabetes drug LixiLan met its late-stage trial target

Novartis bets on demand for new heart-failure drug Entresto

Novartis bets on demand for new heart-failure drug Entresto

By

The FDA approval this week of a new heart-failure drug is expected to spur interest among cardiologists seeking new ways to keep patients with heart failure out of the hospital.

OPINION

Email Newsletters